Opendata, web and dolomites

QUIBIM Precision SIGNED

QUantitative Imaging Biomarkers Medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "QUIBIM Precision" data sheet

The following table provides information about the project.

Coordinator
QUIBIM SOCIEDAD LIMITADA 

Organization address
address: AVENIDA FERNANDO ABRIL MARTORELL 106, TORRE A, BIP FE
city: VALENCIA
postcode: 46026
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://h2020778064.quibim.com/
 Total cost 1˙791˙750 €
 EC max contribution 1˙254˙225 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QUIBIM SOCIEDAD LIMITADA ES (VALENCIA) coordinator 1˙254˙225.00

Map

 Project objective

QUIBIM Precision® is the first imaging biomarkers analysis platform in the cloud presenting innovative whilst extremely useful characteristics for the sector: 1) Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility; 2) Medically certified: QUIBIM are medically valid to scientifically support decision making; 3) Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities 4) Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis, especially from specialists as each report costs 45€.

QUIBIM allows any physician to make more accurate diagnosis by providing additional information extracted from the same imaging sample (tomography, radiology…) already acquired. Our technology based on machine learning and image processing algorithms scout the image and compare it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye.

Regarding out target market: According to WHO , the total supply of physicians worldwide is estimated in 12,7 million. Our priority markets, America and Europe, accounts for 65% (8,26 million physicians) and present the highest level of health expenditure in the world. Within physicians, 43% are General Practitioners and 57% are specialists . Considering specialists, only, the resulting target market size is 4,70 million specialists.

We forecast to generate revenues above €36 million in the 5th year of sales. In terms of employment,we expect to generate more than 150 direct jobs (180 indirect) by that same year.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUIBIM PRECISION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUIBIM PRECISION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Meshporto_smeIns1_2 (2018)

PsstMenu allows customers to place orders directly from home or restaurant tables using only a smartphone.

Read More  

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

SOFT (2017)

SOFT, the first camera-based colorectal cancer screening test to detect occult blood in faeces immediately and with no lab analysis.

Read More